Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

whole genome sequencing

- PMLiVE

One-carbon Therapeutics collaborates with Tempus in cancer treatment

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

Eli Lilly’s Inluriyo approved by FDA for breast cancer

The oral drug can be used to treat advanced or metastatic breast cancer

- PMLiVE

Lilly and Circle Pharma agree to collaborate on new oral macrocycle therapies

The agreement is part of the Lilly Catalyze360 model, designed to empower early-stage biotechs

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

DEBRA and Queen Mary partner to advance epidermolysis bullosa drug development

Around 500,000 people worldwide are affected by the group of rare genetic skin conditions

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links